Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial

Abstract Aims/Introduction Sodium–glucose cotransporter 2 inhibitors reduce bodyweight (BW) by creating a negative energy balance. Previous reports have suggested that this BW reduction is mainly loss of body fat and that ~20% of the reduction is lean mass. However, the effects of sodium–glucose cot...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Hideka Inoue, Katsutaro Morino, Satoshi Ugi, Sachiko Tanaka‐Mizuno, Keiko Fuse, Itsuko Miyazawa, Keiko Kondo, Daisuke Sato, Natsuko Ohashi, Shogo Ida, Osamu Sekine, Masahiro Yoshimura, Kiyoshi Murata, Katsuyuki Miura, Hisatomi Arima, Hiroshi Maegawa, the SUMS‐ADDIT‐1 Research group
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2019-07-01
Edice:	Journal of Diabetes Investigation
Témata:	Bodyweight Sodium–glucose cotransporter 2 inhibitor Treatment drug
On-line přístup:	https://doi.org/10.1111/jdi.12985
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!